ANMCO position paper E-health integration in cardiology clinical care framework Authors: Fabiana Lucà, Gian Franco Gensini, Francesco Gabbrielli, Daniela Aschieri, Michela Barisone, Ilaria Battistoni, Francesco Antonio Benedetto, Claudio Bilato, Giovanni Bisignani, Roberto Ceravolo, Vincenzo Ciconte, Silvana De Bonis, Leonardo De Luca, Stefania Angela Di Fusco, Andrea Di Lenarda, Sandro Gelsomino, Giovanna Geraci, Vered Gil Ad, Mauro Gori, Attilio Iacovoni, Barbara Maria Teresa Mabritto, Massimo Milli, Iris Parrini, Annarita Pilleri, Andrea Pozzi, Carmelo Massimiliano Rao, Carmine Riccio, Patrizia Rocca, Pietro Scicchitano, Marco Vatrano, Francesco Vigorito, Michele Massimo Gulizia, Furio Colivicchi, Domenico Gabrielli, Fabrizio Oliva, Federico Nardi, Massimo Grimaldi Published: 2026 ABSTRACT AbstractThe ongoing digital transformation is reshaping organisational and care delivery models in cardiology, positioning telemedicine as a pivotal tool to address increasing clinical and demographic complexity. This manuscript presents a comprehensive and critical overview of telemedicine applications in cardiovascular care, with a focus on its role in strengthening hospital-community integration, its deployment within hospital-based healthcare systems, and the associated regulatory and operational frameworks. The analysis encompasses the management of chronic cardiovascular conditions, such as heart failure and atrial fibrillation, through telemonitoring, telecontrol, televisit, and teleconsultation. Additionally, it explores the use of digital technologies in post-myocardial infarction follow-up, oral anticoagulation management, preoperative assessment, and care for elderly patients. The review also highlights the challenges and opportunities linked to digital infrastructure, interoperability, data protection, and healthcare professional training. Introduction The ongoing digital transformation has profoundly reshaped healthcare systems, influencing both organisational models and care delivery pathways. In this evolving landscape, telemedicine (TM) has emerged as a key tool to address the growing clinical and demographic complexity of contemporary healthcare, particularly in cardiovascular diseases (CVD).1,2 The management of patients with chronic CVD requires continuity of care, proactive surveillance, and timely clinical intervention, needs that TM is uniquely positioned to fulfil, while simultaneously alleviating pressure on hospital-based services.2 TM is especially relevant in-patient care, as it promotes more equitable access to healthcare services and improves overall quality of care.3 One of its most significant advantages lies in strengthening the integration between hospital-based and community care. By enabling effective home-based management, TM facilitates safer, more structured discharge processes than traditional models. Additional benefits include fewer hospital admissions, particularly among elderly patients, and reduced patient travel, which is especially relevant for frail and geriatric populations.3 When implemented effectively, TM enables the structured and secure sharing of clinical information among specialists, general practitioners, and community healthcare professionals. This fosters a multidisciplinary, patient-centred approach, helping to overcome fragmentation of care pathways, improve coordination of therapies, and enhance long-term disease management. Such an approach is particularly valuable for patients with heart failure (HF), atrial fibrillation (AF), arterial hypertension (AH), and for individuals carrying Cardiac Implantable Electronic Devices (CIEDs).4 Within hospital systems, the progressive integration of TM is also being pursued as a strategy to improve economic sustainability while responding to emerging healthcare needs and maintaining high standards of organisational innovation.4 Through tools such as virtual visits, teleconsultations, telemonitoring, and telecontrol of clinical parameters (see Glossary; Table 1), continuous and regular patient management is now feasible. This enables early detection of clinical deterioration or complications, improves continuity of care, and reduces inappropriate emergency department visits. Moreover, the incorporation of digital technologies into administrative processes offers an additional opportunity to enhance system efficiency and promote equitable access to care. Table 1Essential telemedicine glossaryTermDefinitionAccess ControlSystem that regulates access to sensitive digital resources, allowing their use only by authorised subjects. Essential for protecting clinical data and ensuring regulatory compliance.Access PointDevice enabling wireless connection to a local network is essential to ensure continuity of access to telehealth services in healthcare settings.European Digital AgendaEuropean Union strategy aimed at promoting digital transition, with objectives of equity, security, sustainability, and inclusion, including in healthcare.Aggregated DataSets of statistically reprocessed anonymized data describing population-level phenomena are used for epidemiological studies and healthcare performance analyses.AndroidMobile operating system widely used in digital health to support health-related apps and clinical communication tools.AnonymisationTechnique that removes any direct link between data and the individual’s identity, reducing re-identification risk in secondary-use contexts.Anonymized DataInformation from which all direct identifiers have been removed, enabling research and health statistics under secure conditions.App (Mobile Application)Software installable on mobile devices, useful for monitoring, health education, and clinician–patient communication.GIS ApplicationsSystems managing georeferenced data, applied in public health for territorial epidemiological analyses and service planning.API (Application Programming Interface)Interfaces enabling structured data exchange between software systems are essential for interoperability across healthcare platforms.ASP (Application Service Provider)Model where software is provided remotely, enabling scalable delivery of clinical IT services in telemedicine.Software ArchitectureTechnical structure of an IT system designed to ensure efficiency, security, and scalability of healthcare applications.Assumed ConsentForm of consent based on lack of objection, applicable only in justified circumstances and only after having adequately informed the patients.Virtual ClassroomOnline environment for distance learning that reproduces the educational dynamics of a traditional classroom.Patient EmpowermentProcess that promotes patient autonomy in managing health through informational and digital tools.Strong AuthenticationIdentity verification method based on at least two distinct factors is indispensable for secure access to healthcare platforms.AuthenticationProcedure confirming the user’s identity before authorising access to a system.AuthorisationVerification of access rights to specific resources for authenticated users.TelemedicineDelivery of healthcare services at a distance supported by digital technologies, aiming to improve accessibility, continuity, and quality of care.TelevisitRemote clinician-patient interaction for diagnostic and therapeutic purposes, documented and traceable like an in-person visit. During a televisit, biological parameters may be collected when clinically appropriate; remote monitoring and clinical surveillance can be performed. Televisit is generally intended for follow-up of patients with an established diagnosis and can be delivered when physical examination is not required and when the service is consistent with an Individualized Care Plan (ICP) or PDTA. The physician determines whether and how the televisit can be used, including whether TM may be applied to collect and monitor biological parameters remotely and to ensure clinical surveillance. Within TM services, physicians may also issue medical certificates after verifying the reliability and correctness of collected data. Data and information exchange between the physician and the patient must be ensured. Activation of TM requires the patient’s prior agreement (or that of an authorized family member) to confirm, among other aspects, the availability of telematic contact for document/information interaction with the specialist. During a televisit, a healthcare professional may support the physician. Informed consent must be collected in advance, in compliance with privacy and security requirements. The televisit must guarantee real-time interaction and may be facilitated by a caregiver to support communication. It may be applied in several community-care settings, including outpatient specialist care, counselling services, and mental health centres. Direct clinician–patient interaction via videoconference is essential. The technological complexity used (e.g. phone call, video call, transmission of clinical images such as skin lesions/wounds) must be appropriate to the specific case and determined by the responsible physician.TeleconsultationRemote structured collaboration between healthcare professionals that does not require the patient’s direct presence. It involves sharing clinical data and specialist evaluations to improve diagnostic accuracy or define the most appropriate therapeutic approach in complex cases. This modality allows clinicians to draw on the expertize of colleagues within the same speciality or across different disciplines, facilitating comprehensive case assessment. When clinical conditions allow, teleconsultation may also be performed asynchronously without compromising patient safety.TelemonitoringRemote acquisition and transmission of clinical parameters through connected digital devices represents a key tool in the active management of chronic diseases. Vital parameters are continuously collected via biomedical sensors (with or without direct patient contact) and transmitted to a dedicated platform. Home-based technology is selected based on clinical indications and must ensure continuous connection with the central system, which processes and integrates data and makes them available to healthcare professionals according to defined operational procedures. It is also essential that the collected data are stored locally at the patient’s site to maximize security and availability when needed.Medical Tele-check/TelecontrolStructured activity based on periodic contacts between patient and physician aimed at monitoring clinical evolution. It uses video calls integrated with transmission of home-acquired clinical data, both prior to and during real-time interaction. This approach supports continuous evaluation of health status and enables remote therapeutic monitoring.Medical–Healthcare Tele-advice (Teleconsultancy)Remote clinical-care activity involving two or more healthcare professionals from different disciplines or with different roles related to the case. It is not limited to physicians but includes all legally recognized healthcare professions. It is an on-demand, scheduled intervention designed to provide qualified support for specific clinical situations. Teleconsultancy is delivered through a video call in which the consulted professional provides operational/decision-making support to the requesting clinician to ensure appropriate patient management. The virtual meeting may occur with the patient present or at a subsequent time, provided all relevant clinical information is available, including reports, health data, and imaging documentation. Direct structured interaction between professionals is central, while asynchronous integration of additional information may be allowed when needed. Importantly, teleconsultancy cannot replace emergency or first-aid services; rather, it supports routine clinical practice by promoting knowledge-sharing and continuity of care.TelerehabilitationRemote delivery of personalized rehabilitation programs, digitally monitored and integrated within the therapeutic pathway.TeleassistanceTeleassistance is a professional activity that falls within the specific competences of different healthcare professions and is carried out through remote interaction between the health-worker and the patient or his/her caregiver, for supporting the management of the health condition, promoting well-being and ensuring continuity of care at home or other living environment. It is mainly addressed to people with chronic conditions, with frailty or vulnerability. Teleassistance is generally scheduled and repeatable, in line with individualized care plans. Interaction mainly takes place via videocall between the professional and the patient/caregiver, with the possibility of sharing clinical data, reports, images or other digital content. The professional can also use dedicated applications to administer questionnaires, provide educational materials or share video tutorials to support the performance of specific activities. Teleassistance can also be provided in collaboration with social workers, with a view to integrated and multi-professional care. In this context, teleassistance may involve various qualified healthcare professionals (e.g. nurses, psychologists, nutritionists, physiotherapists, speech therapists, etc.), in response to the specific needs of the person being cared for.Telemedicine PlatformIT system that securely and integrally manages TM activities, ensuring traceability, interoperability, and data protection. Essential telemedicine glossary Given the expanding role of TM in chronic disease management, major international scientific societies, including the American Heart Association (AHA),5 the American College of Cardiology (ACC),6,7 and the European Society of Cardiology (ESC), have progressively incorporated TM into their recommendations, defining its role as complementary to conventional clinical practice.2,8,9 European guidelines recognize that telemonitoring strategies may contribute to reduced rehospitalisation rates and improved therapeutic adherence, particularly when embedded within adequately structured programs supported by trained personnel.2,3 In cardiology, the effectiveness of digital consultations and collaborative care models depends critically on the availability of interoperable systems integrated with electronic health records (EHRs), ensuring secure, continuous, and accessible information flow among all professionals involved. The adoption of standardized data transmission protocols may enhance uniformity in service delivery. However, such standardisation must preserve sufficient flexibility to tailor medical and care interventions to the individual patient, particularly in situations of increased clinical or social complexity. The expansion of digital health services also requires addressing several unresolved challenges, including disparities in access to technology, limited digital literacy, and a lack of robust long-term cost-effectiveness evidence comparing TM with traditional care models. Further harmonisation of technical requirements for commercially available digital devices is needed to achieve a fully integrated system, building on national interoperability frameworks such as the recently launched National Telemedicine Infrastructure. Greater regulatory clarity is also required regarding professional liability and legal responsibilities in remote care settings. Consequently, the sustainable expansion of TM requires an integrated strategy that encompasses technological development, workforce training, regulatory adaptation, and active patient engagement (Table 1). Digital technologies enable continuous, tailored, and multidisciplinary interactions between clinicians and patients, supporting proactive and integrated management of chronic diseases,2 with positive effects on therapeutic adherence, timeliness of intervention, and patient awareness and empowerment, particularly among frail individuals with multiple comorbidities.10,11 TM is fundamentally based on transparency and data sharing, aiming to actively involve patients as partners in clinical decision-making through an ethical and regulated framework that ensures data protection and effective communication.11,12 Importantly, TM should not be viewed as a replacement for traditional physician–patient interactions, but rather as a complementary modality that enhances effectiveness, efficiency, and appropriateness of care. All rights and duties inherent to conventional healthcare services fully apply to TM.3 Beyond informed consent for the healthcare intervention itself, explicit consent for data management is required, clearly specifying how data will be handled, who will have access, and the roles and responsibilities of the institutions and professionals involved. One of the objectives of TM is also to enhance disease awareness and self-management by patients and caregivers, reinforcing their central role in chronic disease management through active engagement and improved understanding of the condition.12 Digital medicine (DM) Digital medicine (DM) represents the evolution, currently in its early stages, of TM from a means of providing remote services to a harmonized set of medical and care activities based on digital technologies, regardless of the distance from which they are delivered. This evolution requires advanced technological infrastructure and specific methodological development. In this context, understanding the scope and domains of DM is essential to evaluate the effectiveness and sustainability of TM-based models within cardiology pathways. Also, the concept of DM began to consolidate after 2010, with a progression that, until approximately 2019, largely paralleled the widespread adoption of smartphones and was mainly centred on the diagnostic opportunities offered by emerging mobile technologies. Subsequently, DM evolved into a methodological framework for generating evidence supporting the clinical use of selected digital technologies, particularly app-based solutions underpinning Digital Therapeutics (DTx). This shift introduced novel development streams in digital healthcare, including digital biomarkers (voice biomarkers to monitor tremor changes in Parkinson’s disease), electronic clinical outcome assessments (e.g. electronic patient-reported outcome questionnaires, ePROs), and tools designed to measure adherence and safety (wearable fall-detection sensors and smart home monitoring systems enabling passive surveillance). This progressive evolution has contributed to the definition currently accepted by the international scientific community. DM may be described as an integrated body of scientific–technological knowledge and clinical competencies that focuses on the appropriate use of digital and robotic technologies in medical practice to innovate care through new modalities of parametric measurement, differential diagnosis, and treatment/intervention, ultimately improving both treatment and prevention. Accordingly, DM has evolved from TM and surgical/assistive robotics, relying on the integrated clinical use of high-quality hardware and software systems. These are increasingly supported by Artificial Intelligence (AI) to analyse large volumes of data and enable predictive modelling of human pathophysiological dynamics, as well as by advances in robotics that aim to optimize care processes. DM employs technological tools, software and hardware capable of producing measurements and/or delivering interventions to treat and/or prevent disease, supported by clinical evidence of efficacy and by approval processes based on scientific validation throughout all development phases13,14 DM is a component of Digital Health (DH), which is defined more broadly as the set of digital technologies applied to health and does not always require evidence of clinical effectiveness or regulatory approval.14 DM products may be categorized into three main groups: Measurement products, namely systems designed to collect information about patients in their real-life context through direct patient input or automatically via sensors, are intended for diagnosis or disease monitoring (e.g. digital biomarkers, systems that monitor pharmacological adherence, digital inhalers, digital pills). Measurement products, namely systems designed to collect information about patients in their real-life context through direct patient input or automatically via sensors, are intended for diagnosis or disease monitoring (e.g. digital biomarkers, systems that monitor pharmacological adherence, digital inhalers, digital pills). Intervention products, used autonomously or together with drugs, devices, or other therapies to optimize care and improve health outcomes (digital drug support tools, CIEDs connected to monitoring systems, digital self-management systems). DTx belong to this category as a subset of DM; they are therapies in which the active ingredient is a software component or algorithm delivered through digital technologies (apps, software, sensors) and classified as medical devices with proven therapeutic efficacy derived from confirmatory randomized controlled clinical trials15-17 (subcutaneous insulin and glucagon pumps, reminder systems for therapy intake, applications delivering structured health education, serious games). A parliamentary intergroup dedicated to DTx has recently been established to accelerate the diffusion of these technologies and promptly identify an effective regulatory pathway enabling reimbursement,16,18 as already occurs in other European Union countries.19 Intervention products, used autonomously or together with drugs, devices, or other therapies to optimize care and improve health outcomes (digital drug support tools, CIEDs connected to monitoring systems, digital self-management systems). DTx belong to this category as a subset of DM; they are therapies in which the active ingredient is a software component or algorithm delivered through digital technologies (apps, software, sensors) and classified as medical devices with proven therapeutic efficacy derived from confirmatory randomized controlled clinical trials15-17 (subcutaneous insulin and glucagon pumps, reminder systems for therapy intake, applications delivering structured health education, serious games). A parliamentary intergroup dedicated to DTx has recently been established to accelerate the diffusion of these technologies and promptly identify an effective regulatory pathway enabling reimbursement,16,18 as already occurs in other European Union countries.19 Combination products, capable of measuring digital biomarkers and delivering therapy based on measured values (e.g. artificial pancreas systems). Combination products, capable of measuring digital biomarkers and delivering therapy based on measured values (e.g. artificial pancreas systems). The implementation of DM can naturally develop within chronic care management through the revision of PDTA (Diagnostic, Therapeutic and Care Pathways), adopting the home setting as a key environment to enhance collaboration with the patient while optimising socio-healthcare interventions via digital technologies. These tools can be integrated alongside traditional strategies across all PDTA phases, from needs assessment and diagnosis to monitoring, rehabilitation, and therapy, supporting continuity of care and enabling digital models for territorial healthcare delivery. Adoption of this model requires disseminating information and providing training for all stakeholders, developing research and clinical experimentation programs, and approving regulations to accelerate DM implementation. Within this context, telemonitoring represents one of the most promising DM tools, allowing clinical observation to shift from hospital to home settings, in accordance with principles of proximity and continuity of care, though it remains one of the most complex approaches to organize (Table 1). Telemonitoring uses audio, video, and other telecommunication technologies to remotely monitor patients, relying on home devices to measure vital signs, CIEDs, and wearables (smartwatches). The collected data should be stored in cloud platforms that can detect threshold exceedances and trigger appropriate healthcare countermeasures, including urgent responses when required. In cardiology, telecontrol is also relevant, referring to structured remote clinical follow-up through scheduled video calls supported by systematic collection of specific clinical data. Televisits are real-time remote medical consultations made possible by an internet connection, enabling video interaction and the secure sharing of patient data through dedicated, certified platforms.20 Teleconsultation refers to remote collaboration among physicians, allowing one clinician to seek advice from one or more colleagues on a specific patient and to share diagnostic and therapeutic decisions collegially (Table 1). Teleconsultation can be defined as a medical act carried out at a distance between healthcare professionals to manage a specific clinical issue and may occur through two main operational modalities21-23 (Figure 1): Asynchronous (store-and-forward): communication does not occur in real time. The referring clinician transmits clinical patient data (history, tests, imaging, reports) through a protected digital system; the specialist reviews the information later and provides a deferred clinical response. Asynchronous (store-and-forward): communication does not occur in real time. The referring clinician transmits clinical patient data (history, tests, imaging, reports) through a protected digital system; the specialist reviews the information later and provides a deferred clinical response. Synchronous (real-time): interaction occurs in real time, for instance, through videoconferencing platforms or dedicated systems, allowing immediate discussion of diagnosis, therapy, and care pathway. Synchronous (real-time): interaction occurs in real time, for instance, through videoconferencing platforms or dedicated systems, allowing immediate discussion of diagnosis, therapy, and care pathway. Teleconsultation. Overview of teleconsultation, showing asynchronous (store-and-forward) and synchronous (real-time) modes for remote physician collaboration and clinical decision support. In both modalities, an essential requirement is that teleconsultation is conducted through secure electronic systems that ensure traceability of the entire process (request and response), with documentation recorded in the official medical record. Although various tools exist for clinical information exchange, systems integrated into institutional electronic health records are generally the most reliable in terms of efficiency, security, and data governance for outpatient remote care delivery. A structured clinical-to-clinical teleconsultation program may improve access to care and potentially influence outcomes. Finally, telerehabilitation refers to the delivery of rehabilitation services at a distance.15 Each of these strategies has distinct objectives, challenges, and limitations24-27 (Table 1). Regulatory references for digital medicine The regulatory framework in this field is still evolving. Although early Italian developments in DM were documented as early as the 1970s through remote electrocardiogram transmission, comprehensive legislative definitions remain limited. Initial regulatory attempts date back to 2007, when the Ministry of Health established the National Observatory for the evaluation and monitoring of eCare applications (Osservatorio eCare), developed in close collaboration with the Emilia-Romagna Region. This initiative was supported by the European Commission Communication COM (2008)689 of 04/11/2008, which aimed to provide legal clarity and promote the implementation of TM across Member States. On 20 February 2014, the State Regions Conference formalized the agreement on the National Guidelines for TM, proposing early models, processes, and modalities for integrating TM into clinical practice. At the European level, this digitalisation process was strengthened by Regulation (EU) 2017/745 on medical devices, one of the first legal instruments to operationally define software applied in medicine. A major acceleration in the development of a national public TM system occurred during the COVID-19 pandemic, driven by operational guidance issued by the National Centre for Telemedicine and New Assistive Technologies at the Italian National Institute of Health. This led to the State–Regions and Autonomous Provinces Agreement Rep. Atti 215/CSR of 17/12/2020, entitled ‘National indications for the delivery of TM services’, and the Agreement Rep. Atti 231/CSR, entitled ‘National indications for the delivery of telerehabilitation services by health professions’. These documents defined core TM services, clarified healthcare responsibilities, and indicated essential organisational and administrative requirements. In Italy, the State–Regions Agreements of 17/12/2020 and 18/11/2021, together with the decree of 29/04/2022 (Official Gazette No.150 of 24-05-2022), defined the organisational model for implementing home care using TM systems. In parallel, the decree of 21/09/2022 (Official Gazette No. 256 of 02-11-2022) and the subsequent decree of 30/09/2022 (Official Gazette No. 298 of 22-12-2022) established the key principles for developing the national TM cloud infrastructure, designed to coordinate TM activities nationwide. These provisions defined minimum functional software requirements underlying regional cloud infrastructures, national interoperability requirements for TM services, and competencies and training needed to ensure DM development and effectiveness within regional healthcare contexts for both professionals and users. Three aspects require further discussion from a regulatory perspective: Professional liability; Professional liability; Privacy and protection of sensitive data; Privacy and protection of sensitive data; Economic reimbursement mechanisms for TM-delivered healthcare services. Economic reimbursement mechanisms for TM-delivered healthcare services. The State Regions Agreement of 17/12/2020 specifies that healthcare professionals delivering DM services assume full professional responsibility for their actions while acknowledging distance-related limitations. Therefore, clinicians must responsibly decide the most appropriate operational approach. Medico-legal liability remains essentially comparable to conventional in-person clinical activities. Regarding reimbursement criteria, uniform guidance is still lacking. The State–Regions Agreement of 17/12/2020 reiterates that remote healthcare services should be remunerated in accordance with national/regional regulations governing LEA, using the same tariff/remuneration system as for the same services delivered through traditional models. In 2016, the Autonomous Province of Trento was the first to formally quantify reimbursement for TM services. Notably, TM does not include triage or phone-based advice performed solely to identify diagnostic/therapeutic pathways and schedule visits. Access regulations for televisits overlap with those established nationally and regionally for equivalent in-person services, including tariff and remuneration, which follow the same rules as traditional delivery. For each TM service, an official clinical report must be produced. Artificial intelligence in cardiology The evolution of TM is now closely intertwined with the development of digital technologies, particularly AI. While early TM services primarily focused on the remote transmission of clinical data and distance-based decision support, the integration of AI has opened new opportunities for advanced analytics, personalisation, and prediction, thereby improving the efficiency and accuracy of diagnostic and therapeutic pathways. In this setting, AI does not merely optimize existing systems; it introduces a paradigm shift in both healthcare delivery models and the generation of medical knowledge. Synthetic AI (sAI), which generates realistic clinical data using generative models such as Generative Adversarial Networks (GANs), represents a novel and promising frontier for overcoming the main limitations of real-world clinical datasets, including scarcity, heterogeneity, and ethical and privacy constraints.28 In cardiology, sAI is particularly attractive due to the availability of large amounts of structured data, imaging, and complex data-driven information. Nonetheless, these tools are still frequently viewed with scepticism, largely due to concerns regarding limited reliability.29 This perception is further reinforced by prior experiences in which some models were developed without meaningful clinician involvement, resulting in solutions that, despite considerable engineering sophistication, proved difficult to use and insufficiently applicable to real-world clinical practice.30 Importantly, the perceived reliability of synthetic data strongly depends on the active integration of clinicians throughout the generative process. In the absence of clinical supervision, models may generate incoherent or clinically unrepresentative data, thereby undermining practical utility and eroding clinical trust.31 Confidence among healthcare professionals in sAI requires transparent, clinically supervised, and verifiable frameworks, components that remain too often lacking in current implementations.31 The perceived reliability of synthetic data largely depends on physicians’ involvement in the generative process. Without active clinical oversight, models may produce data that are inconsistent or insufficiently representative of real clinical scenarios, reducing their practical value and weakening clinical confidence.32 Trust in artificial intelligence systems (AIS) among healthcare professionals requires transparent, clinically supervised, and verifiable frameworks, which are still lacking in many current implementations.32 A structured example of this approach is the TIMA (Team-Implementation Multidisciplinary Approach) method, which conceptualizes synthetic data generation as an iterative process. Within this framework, clinicians define the relevant clinical constraints, assess the coherence of relationships among variables, and evaluate the plausibility of the generated cases.31,32 As shown in Figure 2, the workflow explicitly incorporates supervision and feedback between the clinical team and developers, thereby increasing confidence in the reliability of the resulting dataset. Multidimensional framework for the generation, validation, and clinical use of synthetic health data. The figure depicts an operational workflow that begins with a multidisciplinary team defining clinical and methodological constraints and continues through ongoing interaction between clinical expertise and computational development. Subsequent stages involve creating and assessing synthetic datasets, including analysis of internal consistency, practical usability, and alignment with clinical standards. This approach embeds medical reasoning within generative algorithms, ensuring that synthetic data are not only statistically reliable but also clinically credible. Accordingly, the responsible and safe adoption of sAI entails a cultural and methodological transformation in which clinicians serve as key drivers rather than passive end-users. Televisit Current regulations define a televisit as ‘a medical act in which the healthcare professional interacts remotely, in real time, with the patient, also with the support of a caregiver’. The physician is responsible for deciding in which situations and to what extent TM may be used to benefit the patient, and for employing TM tools to measure or remotely monitor biological parameters and for clinical surveillance.33 Televisits may be prescribed exclusively for follow-up activities in patients whose diagnosis has already been established during an in-person consultation. Accordingly, services delivered through televisits aim to: follow up a known condition (the first visit must always be conducted in the traditional in-person setting and not as a televisit); follow up a known condition (the first visit must always be conducted in the traditional in-person setting and not as a televisit); monitor, confirm, adjust, or modify ongoing therapy; monitor, confirm, adjust, or modify ongoing therapy; Perform an anamnestic evaluation to prescribe diagnostic tests or staging investigations for a known or suspected condition; Perform an anamnestic evaluation to prescribe diagnostic tests or staging investigations for a known or suspected condition; allow the physician to review the results of completed investigations, which may be followed by the prescription of further diagnostic assessments and/or therapy. allow the physician to review the results of completed investigations, which may be followed by the prescription of further diagnostic assessments and/or therapy. Cardiology is among the specialities in which televisits are most widely implemented, as an integration of standard in-person visits.34-37 For example, cardiology televisits may be used in patients with chronic CVD (HF, ischaemic cardiomyopathy) for scheduled follow-up assessments, therapy prescriptions or adjustments, particularly for treatments requiring AIFA monitoring, and for the prescription and/or review of instrumental tests.38 Essential components of televisit delivery include careful patient selection and the patient’s (or legal guardian’s) informed consent, to confirm the availability and accessibility of a synchronous audio–video communication system that enables the secure exchange of data, images, and clinical documents.39 The efficiency of IT systems, prior training of citizens in DH tools, and continuous support provided to patients and/or caregivers during technology use positively influence satisfaction with the service, including among older age groups.33 Importantly, the televisit process does not end with the activation of a video call; rather, the service follows the full life cycle of the prescription (prescription, booking, delivery, reporting, and administrative accounting), in accordance with the regulatory framework governing outpatient specialist care and specific regional regulations.40 The entire pathway—from patient consent to service accounting is designed to avoid any physical access to healthcare facilities by the patient or caregiver (Figure 3). Televisit. Key indications and essential requirements for conducting a televisit in routine clinical practice. The implementation of this new model of care requires organisational restructuring, the development of new competencies among healthcare professionals, and the emergence of additional professional profiles to be integrated within healthcare organisations (e.g. management engineer and/or biomedical engineer). While the recent pandemic facilitated the expansion of TM,41 particularly televisits, the current challenge is to develop new healthcare models that leverage technological tools to redesign socio-clinical care pathways.42 Clinical governance models in cardiovascular telemedicine The effectiveness and safety of telemedicine in cardiology depend strongly on a clearly defined clinical governance framework that establishes roles, responsibilities, and decision-making processes throughout the care pathway. TM should not be regarded as a purely technological or administrative service; rather, it must be embedded within structured clinical organisational models aligned with established diagnostic, therapeutic care pathways and the professional responsibilities of conventional clinical practice. The general principles, organisational structure, and decision-making processes that characterize clinical governance in cardiovascular telemedicine are illustrated in Figure 4. In addition, clinical governance in TM must ensure effective integration between hospital and community care, while maintaining a clear allocation of clinical responsibilities (Figure 4). Within this organisational framework, each telemedicine program in cardiology should operate under a formalized clinical governance model characterized by explicit specialist leadership, multiprofessional integration, and a clearly defined distribution of clinical accountability. Clinical governance framework, organisational structure, and decision processes in cardiovascular telemedicine. Clinical responsibility for telemedicine services remains with the cardiology specialist, in continuity with in-person care. Telemonitoring, televisits, and teleconsultations are fully recognized clinical acts and must meet the same standards of appropriateness, traceability, reporting, and medico-legal accountability. Technology functions as an enabling tool within the care process but does not replace clinical judgment or medical decision-making. The organisational model includes a reference cardiology centre (HUB or equivalent) responsible for clinical oversight, protocol definition, and activity supervision, supported by structured multiprofessional teams with clearly defined roles and shared protocols for patient enrollment, alert management and prioritisation, and escalation to in-person reassessment or higher levels of care when needed. Alerts generated by telemonitoring systems are filtered according to predefined clinical criteria and integrated into a structured decision pathway distinguishing nursing assessment, specialist evaluation, and therapeutic decision-making, with all actions documented in the patient’s official medical record to ensure appropriateness, continuity of care, and clinical accountability. Only with a structured governance framework can TM ensure appropriateness, safety, sustainability, and genuine clinical value within CV care pathways. Clinical governance models are therefore essential prerequisites for the appropriate implementation of telemedicine in cardiology. On this basis, its application can be examined across the most relevant clinical settings. Consistent with these principles, TM in cardiology may be implemented through different organisational models that translate clinical governance into concrete operational structures across diverse care contexts (Figure 5). Hospital–community telemedicine network and HUB & SPOKE model with specialist cardiology governance. Clinical governance in telemedicine should promote effective integration between hospital and community care while maintaining a clear allocation of responsibilities: the cardiology specialist remains the primary clinical reference, whereas community care providers (general practitioners and community nursing services) operate within a functionally integrated, protocol-driven framework. Information flows must be bidirectional, secure, and interoperable. Within this context, structured clinical governance models are essential for the appropriate implementation of telemedicine in cardiovascular care pathways. The HUB & SPOKE model with specialist cardiology governance represents a recommended organisational approach, in which effectiveness depends not only on technological availability but also on alignment with established diagnostic–therapeutic care pathways and clearly defined governance structures. This model is particularly applicable to chronic heart failure, atrial fibrillation, remote monitoring of implantable cardiac devices, and high-risk post-discharge follow-up. Its main strengths include clear attribution of clinical responsibility to the cardiology specialist, consistency with international scientific society recommendations, mitigation of medico-legal risk, and ease of integration into existing care pathways. Potential challenges include the need for adequate resource allocation in HUB centres and the risk of organisational overload in the absence of structured alert management systems. Applications of digital medicine in cardiology HF is a growing challenge for healthcare systems, primarily due to frequent clinical decompensations and prolonged rehospitalisations, with a substantial impact on patients’ quality of life and healthcare expenditure43,44 Alongside population ageing and continuous advances in cardiovascular (CV) therapies, identifying treatments that are not only effective but also applicable across heterogeneous patient profiles20 has become increasingly complex. Therefore, collaborative efforts are required to refine HF management strategies and improve long-term outcomes. The COVID-19 pandemic led to a profound organisational reshaping of hospitals and served as a major catalyst for implementing TM,45-47 particularly in conditions such as HF. In this setting, TM may support therapeutic decisions, reduce the risk of hospitalisation, and ensure continuity of care by enabling early recognition of new-onset or worsening signs and symptoms, while reducing avoidable face-to-face visits. Several TM strategies have been described for patients with HF,20 including telemonitoring, teleconsultation, televisits, and telerehabilitation. The use of TM in HF has been associated with reductions in both all-cause mortality and hospitalisations.26,27 Among the available approaches, telemonitoring has gained particular relevance, as dedicated algorithms for early detection of HF deterioration may help identify individuals at higher risk of acute decompensation.48 In the PARTNERS HF study,49 which included approximately 700 patients with implantable cardioverter-defibrillators (ICDs), a multiparametric analysis identified patients with a 5.5-fold higher risk of HF-related hospitalisation within 30 days. Additional studies have supported a role for telemonitoring in lowering rehospitalisation rates.50,51 Importantly, the burden of HF extends beyond the number of admissions, as prolonged length of stay has major socio-healthcare implications. In this regard, telemonitoring has also been associated with shorter hospitalisations: the CONNECT trial52 demonstrated a significant reduction in hospital length of stay among patients managed with telemonitoring compared with standard in-office follow-up (P & 0.002). A clinically relevant survival benefit associated with telemonitoring was reported in the randomized IN-TIME trial53 (Influence of Home Monitoring on the Clinical Status of Heart Failure Patients With an Impaired Left Ventricular Function), which enrolled 664 patients with mild-to-moderate HF implanted with cardiac resynchronisation therapy pacemakers (CRT-P) and cardiac resynchronisation therapy defibrillators (CRT-D). Worsening of the composite clinical score (all-cause death, HF hospitalisation, NYHA class, and patient global self-assessment) occurred in 63/333 patients (18.9%) in the remote arm compared with 90/331 (27.2%) in the standard-care arm (P = 0.013; OR 0.63; 95% CI 0.43–0.90). This translated into a significantly lower 12-month mortality (3.0% vs. 8.2%; HR 0.36; 95% CI 0.17–0.74; P = 0.004). Real-world evidence from large databases involving more than 200 000 patients (ALTITUDE54 and MERLIN55) further confirmed a major impact of telemonitoring on survival, with a 50–75% reduction in mortality risk among patients managed remotely compared with those receiving standard follow-up. In contrast, evidence is less consistent in patients with advanced HF undergoing CRT-D implantation. Available data in this subgroup largely derive from the MORE-CARE study,56 which enrolled patients candidates for CRT-D only. A comparison between the two randomized trials (IN-TIME53 and MORE-CARE56) highlights differences not only in baseline population profiles but also in the operational organisation of telemonitoring. In MORE-CARE, actions triggered by telemonitoring alerts were left to routine centre-based clinical practice, whereas in IN-TIME, alerts were managed through a central monitoring unit acting as a supervisor. Moreover, MORE-CARE56 relied on a limited set of active alerts (AF and intrathoracic impedance), whereas IN-TIME implemented a broader multiparametric model that included supraventricular and ventricular arrhythmias, low pacing percentage, burden of premature ventricular contractions, and reduced patient activity. These observations suggest that a structured daily multiparametric approach—consistent with the IN-TIME organisational model, may be more likely to have a favourable impact on outcomes. Based on the available evidence, the IN-TIME strategy has been incorporated within European guideline frameworks among the main organisational models proposed by clinical studies (MONIC, HUB&SPOKE model57; HOMEGUIDE, Primary Nursing model; IN-TIME model). Current European Society of Cardiology (ESC) guidelines assign remote telemonitoring a Class IIb recommendation for HF, given its potential to reduce rehospitalisation and mortality (Class IIb, Level of Evidence B).9,58,59 In addition, pulmonary artery pressure monitoring in selected symptomatic patients has shown potential to improve clinical outcomes.60 Although HF is a setting where the generalisability of intervention efficacy may be challenging, telemonitoring offers meaningful advantages that are most likely to translate into clinical benefit when supported by multiparametric integration, appropriate adherence, and incorporation into multidisciplinary care models. Identifying predictive parameters and/or multiparametric risk scores and integrating telemonitoring systems optimally into multidisciplinary pathways remain key goals for future development. TM may also strengthen adherence to guideline-directed medical therapy in HF through regular and structured communication between the patient and the care team. Nevertheless, practical barriers continue to limit routine implementation,20 including the need for adequate hardware (computer, smartphone, tablet) and reliable internet access. Some patients may struggle to use the required devices or participate in TM sessions without assistance due to older age, hearing impairment, or cognitive dysfunction. Furthermore, some individuals may prefer in-person visits to virtual assessments.61,62 Despite these limitations, it is clear that digital solutions are increasingly needed to address persistent gaps in HF care,63 including difficulties with titration and optimisation of therapies in patients with reduced ejection fraction. It is therefore plausible that TM will play an expanding role in the future.64 TM is also a key component of the integrated management of AF, both for early detection of subclinical episodes in high-risk individuals and for structured follow-up of patients with established AF, with potential benefits for therapeutic adherence, rhythm monitoring, and prevention of complications.61,62 The Heart Rhythm Society (HRS) consensus document recommends telemonitoring (Class I, Level of Evidence A) to quantify arrhythmic burden and enable early identification of AF. Telemonitoring sensitivity for early AF detection is approximately 95%,20 and nearly 90% of AF episodes triggering alerts are asymptomatic.63 Compared with standard in-office follow-up, telemonitoring enables arrhythmia detection 1–5 months earlier, supporting dynamic patient management and timely therapeutic adjustments, including initiation of anticoagulation when indicated, rhythm control evaluation, device reprogramming, optimisation of biventricular pacing, and reduction of inappropriate shocks.65,66 A relevant impact of early arrhythmia detection through telemonitoring on hospitalisation rates was reported in the COMPAS study,67 where hospitalisations for atrial arrhythmias were markedly reduced among patients managed with telemonitoring (7.3% in the control group vs. 2.4% in the telemonitoring group). Although not specifically designed for this endpoint, COMPAS also recorded a reduction in cerebral ischaemic events (3.3% vs. 0.8%). In the TRUST study, AF episodes were identified 34.5 days earlier in telemonitoring-managed patients compared with controls (5.5 vs. 40 days). This may have important implications for the management of silent AF, particularly regarding timely anticoagulation initiation and prevention of embolic events. Further dedicated studies are needed to clarify the magnitude of benefit of telemonitoring in this setting. Additional evidence, including the EMBRACE substudy68 and ASSERT findings,69 confirmed that early detection of subclinical AF through telemonitoring is associated with increased use of preventive strategies, especially among patients at high embolic risk68,69 Moreover, integrated digital platforms enable continuous follow-up for patients with known AF, improving adherence and facilitating timely action in case of recurrence, with potential benefits on quality of life and clinical outcomes.70 TM has also gained importance in post-acute coronary syndrome (ACS) care. The period following an ACS represents a particularly vulnerable phase and a cornerstone of secondary prevention, which begins at discharge and continues throughout follow-up. In this context, telemonitoring after hospital discharge has been shown to improve clinical outcomes.71 In the UK TELE-ACS trial,72 337 patients discharged after ACS were randomized to standard follow-up or standard follow-up plus TM, including a wearable ECG system, an automated blood pressure monitor, and a pulse oximeter. When symptoms were reported, a cardiology televisit was performed to determine whether the patient should be directed to the emergency department, the general practitioner, or other services. Telemonitored patients showed lower six-month rehospitalisation rates, fewer emergency department accesses, fewer unplanned coronary revascularisations, and reduced symptom burden.72 In a study enrolling 1064 patients with ACS, digital health interventions (DHIs), including smartphone applications, a smartwatch, and home blood pressure monitoring during hospitalisation and for up to 30 days after discharge, were associated with fewer 30-day rehospitalisations than usual care.73 Overall, TM in the post-infarction setting has been shown to improve adherence, optimize risk factor control, and reduce rehospitalisation.74 By combining telemonitoring, virtual assessments, and mobile applications for remote follow-up, early recognition of symptoms and clinical destabilisation becomes feasible, allowing rapid intervention, particularly during the first 30 days after discharge, which represents the most delicate period and may influence CV outcomes.75 TM also promotes multidisciplinary management through teleconsultation. Long-term benefits of telemonitoring systems have also been reported for quality of life and survival.76 In the field of thrombosis and haemostasis, TM-based follow-up for patients receiving oral anticoagulation, including both vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs), has been associated with improved adherence and treatment quality, as well as reduced bleeding complications and thrombotic recurrences75-80 Home monitoring of haematochemical parameters allows smoother management, especially in elderly or frail individuals,81 enhancing safety and continuity of care, an aspect that became particularly evident during the COVID-19 pandemic.79 Finally, in the context of atherosclerotic CVD, appropriate management of dyslipidaemia is essential to significantly reduce CV risk in both primary and secondary prevention82,83 DM can support several components of dyslipidaemia management, from diagnostic assessment to treatment and monitoring.84 From an epidemiological perspective, analysing data extracted from digital systems using International Classification of Diseases (ICD) coding, typically adopted for administrative purposes, provides accurate insights for conditions such as ACS and HF, but appears less reliable for identifying dyslipidaemia,85 even when ICD coding is combined with lipid-lowering prescriptions and laboratory results. At the individual level, wireless devices and applications on smartphones and tablets can increase awareness of the CV impact of dyslipidaemia and provide rapid access to information on CV risk86,87 Such tools may also facilitate lifestyle modification. In a randomized clinical trial, regular text messages containing behavioural suggestions and motivational reminders related to CV health were associated with a greater reduction in low-density lipoprotein cholesterol (LDL-C) compared with the control arm.88 In a large cohort study, remote titration of antihypertensive and lipid-lowering therapies using digital applications, with the support of pharmacists and digital navigators (dedicated personnel assisting patients in app use), was associated with better control of both blood pressure and LDL-C levels compared with the control group managed through educational interventions in addition to standard in-person follow-up.89 From the clinician’s perspective, CV risk calculators available online or as downloadable applications are valuable tools for quickly and accurately defining an individual patient’s risk profile and tailoring LDL-C targets accordingly. Role of telemedicine in preoperative cardiology consultation The purpose of preoperative CV assessment in non-cardiac surgery is to prevent perioperative CV morbidity and mortality and to minimize bleeding complications.90 The application of TM to this specific cardiology setting gained major momentum during the COVID-19 pandemic, largely because elective surgical procedures needed to be prioritized and, when appropriate, postponed to support strict hygiene measures and social distancing policies.91 Outside the pandemic context, however, TM use in Italy has been described as largely ‘episodic and artisanal’; therefore, in the absence of consolidated local experience and dedicated evidence, its contribution to preoperative risk stratification remains essentially unexplored. Most Italian TM and telemonitoring initiatives have been implemented within chronic CV care,92 particularly in patients with HF93–95. In such scenarios, the patient is typically well known to the care team, and TM enables structured home follow-up by detecting new signs and/or symptoms and documenting disease progression, thus supporting treatment optimisation. In contrast, assigning TM a central role in previously unknown patients—where physical examination and rapid clinical decision-making are pivotal, as in emergency/urgent surgery and, in part, in time-sensitive procedures, appears premature at present and would require seamless hospital, community integration together with robust organisational and technological support. Conversely, a more realistic and immediately applicable role for DH may be envisioned in elective surgery, where both teleconsultation and televisits could be incorporated into the preoperative workflow. In line with the 2022 ESC Guidelines,90 TM, despite the inherent limitation of excluding direct physical examination, allows the acquisition, remote transmission, and interpretation of key cardiocirculatory parameters (blood pressure, heart rate, ECG, biomarkers), facilitates collection of relevant pre-admission information (presence/absence of CV risk factors and known CVD), and may therefore contribute to preoperative CV evaluation. A televisit can also support the assessment of newly developed or previously unrecognized symptoms such as dyspnoea, oedema, and chest pain; allow a structured appraisal of patient-reported functional capacity; and optimize therapy through clear instructions on perioperative medication management. Overall, this approach may enable at least partial CV risk stratification and support the indication for additional face-to-face cardiology work-up, potentially complemented by targeted diagnostic testing. In patients with CIEDs, TM may be particularly valuable for identifying electrical instability (non-sustained ventricular tachycardia or asymptomatic ventricular tachycardia) and early signals of haemodynamic deterioration suggestive of impending HF decompensation (impedance changes).93 Telemonitoring can help detect patients at risk of electrical or haemodynamic instability, support optimisation of medical therapy, and potentially reduce the risk of perioperative CV events, including major arrhythmias and acute HF.94-99 Nevertheless, digital tools are unlikely to replace a model of care in which direct physician–patient interaction remains essential. Rather, they may serve as complementary components of the traditional preoperative approach. At a time when healthcare systems face increasing pressure to reallocate and rationalize available resources, remote consultation has the potential to redesign the organisation and scheduling of preoperative cardiology assessments.100 Adequate technological infrastructure, effective hospital, community integration, appropriate training, and a transparent and equitable governance framework for health data will form the foundations for the safe and appropriate implementation of televisits and teleconsultation in preoperative CV evaluation. Conclusions TM has become a core component of contemporary cardiology, providing innovative solutions to support integrated, continuous, and personalized management of patients with chronic CV conditions. The use of digital tools, such as telemonitoring, televisits, and teleconsultation, has been associated with improved clinical outcomes, particularly through reductions in rehospitalisation rates, enhanced therapeutic adherence, and optimisation of care pathways, most notably in HF and AF. However, its application extends beyond these settings to include post-ACS follow-up, preoperative CV assessment, and management of elderly patients. Nevertheless, the full integration of TM into routine clinical practice requires overcoming persistent technological and regulatory barriers. This transition presupposes the development of essential prerequisites, including digital training for healthcare professionals and improved digital literacy among patients. Targeted actions in this direction are indispensable, and scientific societies are expected to play a decisive role in promoting the structured incorporation of DM into regional and national healthcare systems. In a context where healthcare demand continues to rise and health system sustainability is increasingly challenged, TM should be viewed not merely as an opportunity, but as a necessity. To fully realize its potential, a multidisciplinary, patient-centred approach is required, grounded in scientific evidence, responsible innovation, and a system-level vision.